https://www.aigom.it/wp-content/uploads/2026/06/ART9.6.png501400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-06-09 09:50:562026-06-09 09:50:56FINAL ANALYSIS RESULTS AND PATIENT-REPORTED OUTCOMES FROM DESTINY-LUNG02-A DOSE-BLINDED, RANDOMIZED, PHASE 2 STUDY OF TRASTUZUMAB DERUXTECAN IN PATIENTS WITH HER2-MUTANT METASTATIC NSCLC
https://www.aigom.it/wp-content/uploads/2026/05/ART26.5-1.png431400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-26 08:14:012026-05-26 08:15:37PREVALENCE AND REACTIVATION OF HEPATITIS B AND C IN PATIENTS UNDERGOING CHEMOTHERAPY FOR SOLID TUMORS.
https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-19-095945-Copia.png480600Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-19 08:01:482026-05-19 08:01:48ERADICATION OF HELICOBACTER PYLORI IN THE PRIMARY PREVENTION OF GASTRIC CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-12-122913.png633400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-12 10:31:232026-05-12 10:31:23RISK OF BREAST CANCER AFTER OVARIAN CANCER IN WOMEN WITH A PATHOGENIC/LIKELY PATHOGENIC VARIANT IN BRCA1 OR BRCA2.
https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-05-104358.png400311Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-05 08:28:522026-05-05 08:49:21PEMBROLIZUMAB OR PLACEBO WITH CHEMORADIOTHERAPY FOLLOWED BY PEMBROLIZUMAB OR PLACEBO FOR NEWLY DIAGNOSED, HIGH-RISK, LOCALLY ADVANCED CERVICAL CANCER (ENGOT-cx11/GOT-3047/KEYNOTE-A18): A RANDOMISED, DOUBLE-BLIND, PHASE 3 CLINICAL TRIAL.
https://www.aigom.it/wp-content/uploads/2026/04/Screenshot-2026-04-21-104313.png448400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-04-21 08:45:252026-05-05 08:59:07ADJUVANT RIBOCICLIB PLUS NONSTEROIDAL AROMATASE INHIBITOR THERAPY IN PATIENTS WITH HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER: 5-YEAR FOLLOW-UP OF NATALEE EFFICACY OUTCOMES AND UPDATED OVERALL SURVIVAL.
https://www.aigom.it/wp-content/uploads/2026/04/ARTAPRILE.png458400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-04-13 16:47:532026-05-05 09:05:28ROMIPLOSTIM VERSUS PLACEBO FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
https://www.aigom.it/wp-content/uploads/2026/04/Screenshot-2026-04-08-115157.png711442Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-04-08 09:48:552026-04-27 08:06:4415 GIUGNO 2026-AIGOM LE NOVITA’ DA CHICAGO 2026: L’EVOLUZIONE DELLE CONOSCENZE IN ONCOLOGIA
https://www.aigom.it/wp-content/uploads/2026/04/Screenshot-2026-04-08-112946.png1060748Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-04-08 09:43:472026-04-08 09:43:47AIGOM 2026: NOVITA’ NEL TRATTAMENTO DELLE NEOPLASIE GINECOLOGICHE, VERONA 21 APRILE 2026
